Syntegon Packaging Technology’s subsidiary, Pharmatec, is proud to announce the launch of the new Modular Bioprocessing Platform (MBP), a state-of-the-art solution designed to address the intricate challenges of biopharmaceutical production. As an entirely integrated and automated platform, the MBP offers unparalleled flexibility for the production of biologic drug substances, catering to a diverse range of applications including microbial and mammalian cell culture, proteins, peptides, oligonucleotides, plasmid DNA, and recombinant vaccines.
The development of the MBP is aimed at streamlining production timelines and reducing costs, all while upholding the exceptional quality associated with products ‘made in Germany’. Christian Lavarreda, global product manager at Pharmatec, underscores the mounting pressure on biopharmaceutical companies to implement advanced production capabilities within short time frames.
An essential feature of the MBP is its prefabricated integrated cleanroom design, with all peripheral technology situated outside the cleanroom in technical skids. This approach guarantees full functionality for both clinical and commercial production, with precise temperature control, seamless interfaces for ancillary systems, and user-friendly interfaces for enhanced operability. Additionally, the platform incorporates hygienic and sustainable design elements, including integrated and fully automated cleaning in place (CIP) and filter integrity testing (FIT) functionalities, demonstrating Pharmatec’s unwavering commitment to sustainability throughout the equipment’s lifecycle.
The modular design of the MBP facilitates efficient scale-up from clinical to commercial production, with advanced control strategies for improved process characterization and seamless tech transfer. Moreover, the platform offers advanced analytical functions for predictive product quality assessments and comprehensive production line analyses, enabling continuous optimization of production processes.
Pharmatec remains devoted to the continual enhancement of the MBP, with plans to introduce new and improved functions and options. The modular concept of the platform also ensures the ability to quickly and efficiently incorporate functionalities or capacity in the future, ensuring its sustained lifecycle and relevance in the ever-evolving biopharmaceutical industry.